Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Study Published in PNAS Confirms Potential Utility of Marillion´s Nanoparticle Technology for Tumor Targeting Agents

28.11.2005


Findings in the Prestigious "Proceedings of the National Academy of Sciences" Describe How Natural Nanoparticles Can Be Adapted to Fight Cancer



Marillion Pharmaceuticals, an emerging biotechnology company developing cancer therapeutics, announced that the science underlying its core technology was published in the "Proceedings of the National Academy of Sciences" (PNAS), a peer-reviewed journal. Marillion´s nanoplatform conjugates tumor-homing molecules to naturally occurring nanoparticles responsible for lipid transport throughout the body. The adapted nanoparticles are able to deliver anti-cancer drugs directly into tumor cells. The technology was developed by scientists from the University of Pennsylvania who helped found the company and who are co-authors of the scientific study published in the PNAS.

Marillion´s nanoparticles, called conjugated lipoproteins, are less than 25 nm in diameter, more than 10,000 times smaller than the width of a human hair. Because of their small size they can pass through blood vessel walls to ferry their cargo of anti-cancer drugs to targeted receptors and directly into the cancer cells, leaving the surrounding healthy tissue unaffected.


"We have shown that we can empty these naturally occurring nanoparticles, fill them with chemotherapeutic and imaging agents and then re-route them away from their natural receptors directly to tumor cells," says Gang Zheng, Ph.D., University of Pennsylvania researcher and Marillion co-founder.

There is a great deal of research activity underway attempting to apply nanoparticle technology to cancer therapy. However, many of the nanoparticles currently being developed are synthetic and may themselves prove toxic to the body, precisely because of their ultra-small size and complex interactions with tissues. Marillion intends to avoid these problems by adapting naturally occurring nanoparticles, which are less susceptible to these toxic effects.

Jerry Glickson, Ph.D. also at the University of Pennsylvania and a co-founder of Marillion, added, "As described in the journal, the targeting entity in this study was folic acid, which binds to specific receptors found on certain types of cancers and directs the nanoparticle to the tumor. Other targeting entities can also be attached to guide the nanoparticles to alternate tumors or to the tumor vasculature, where agents can be delivered that fight the cancer by literally starving the tumor of it´s essential blood supply. The particles´ trajectory through the body can also be tracked by attaching imaging agents to the nanoparticle, providing the potential for an innovative ´see and treat´ approach to cancer therapy."

Marillion´s natural nanoparticles have a number of potential advantages. They are completely biodegradable, have a long half-life in the circulation, can be used with numerous types of targeting agents, are capable of delivering a variety of different types of drugs, and are multifunctional, allowing them to be "loaded" with imaging and therapeutic agents both inside and on the surface of the nanoparticle. Marillion is currently using its nanoparticles to carry the widely used chemotherapeutic drug paclitaxel into ovarian tumors, and it plans to initiate clinical trials with its first nanoplatform-based drugs within the next two years.

"Our natural nanoparticles can be designed to act as miniature drug-laden missiles that are small enough to target tumor cells, yet are expected to be devoid of immunogenic and other adverse effects on the body," said Zahed Subhan, Ph.D., J.D., CEO of Marillion. "The results reported in PNAS bode well for the development of our practical nanoparticle-based approach to improving treatment and outcomes for many cancer patients."

The article titled "Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents" initially appeared in the PNAS on-line edition on November 23, 2005. Co-authors Dr. Gang Zheng, assistant professor in the department of radiology and Dr. Jerry Glickson, director of molecular imaging and professor of radiology, biochemistry & biophysics, are both at the University of Pennsylvania.

About Marillion

Marillion Pharmaceuticals is a dynamic pharmaceutical company dedicated to the discovery, development and commercialization of anticancer drugs based on proprietary tumor targeting technologies licensed exclusively from the University of Pennsylvania. The company is building a pipeline of drugs that are designed to selectively target tumor cells so that they are significantly more effective in killing diseased cells and less toxic to healthy tissues than conventional therapies.

Contact:
Ellen Semple
BioAdvance
+1 215.966.6207

Contact:
Barbara Lindheim
GendeLLindheim BioCom Partners
+1 212.918.4650

| directnews
Further information:
http://www.marillionpharma.com

More articles from Studies and Analyses:

nachricht A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg

nachricht Urbanization to convert 300,000 km2 of prime croplands
27.12.2016 | Mercator Research Institute on Global Commons and Climate Change (MCC) gGmbH

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Explaining how 2-D materials break at the atomic level

18.01.2017 | Materials Sciences

Data analysis optimizes cyber-physical systems in telecommunications and building automation

18.01.2017 | Information Technology

Reducing household waste with less energy

18.01.2017 | Ecology, The Environment and Conservation

VideoLinks
B2B-VideoLinks
More VideoLinks >>>